The European Commission has appointed Cathalijne van Doorne, EFNA Vice-President, to the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA).
EFNA is pleased to announce that Cathalijne has been selected to act as the member representing patient organisations for three years, starting from March 1st 2019.